Research Paper Volume 16, Issue 3 pp 2848—2865
Mechanism of Erianin anti-triple negative breast cancer based on transcriptomics methods and network pharmacology
Figure 2. Erianin inhibits the progression of TNBC cells in vitro and in vivo. MDA-MB-231 (A) and 4T1 cells (B) were treated with different concentrations of Erianin for 24 hours, and then the viability was determined using the CCK-8 assay. (C) The migration capacity of MDA-MB-231 and 4T1 cell with Erianin was detected by wound-healing assay. (D) Statistical analysis of wound-healing assay. (E) MDA-MB-231 cells were injected into Balb/c nude mice in situ, and xenograft tumors were imaged after Erianin treatment. (F) Tumor volume in each group (N = 5). (G) 4T1 cells were injected into Balb/c normal mice in situ, and xenograft tumors were imaged after Erianin treatment. (H) Tumor volume in each group (N = 5).